SCN10A-短转录本基因治疗恢复传导并预防恶性心律失常
本研究评估SCN10A-短转录本(S10s)基因治疗能否增加心脏钠电流(INa)并预防心律失常。在Scn5a单倍不足小鼠中,S10s过表达增加INa、动作电位上升速率和振幅, rescue传导减慢;在野生型小鼠中预防缺血再灌注诱发的室性心动过速;在人类诱导多能干细胞来源心肌细胞和模拟人心室模型中亦显示抗心律失常潜力。结论提示S10s基因治疗可能有效治疗心脏传导异常及相关心律失常。
要点
- S10s基因治疗增加Scn5a单倍不足小鼠心肌细胞INa并改善传导。
- S10s在野生型小鼠中预防缺血再灌注诱发的室性心动过速。
- S10s在人类iPSC-CM和模拟人心室模型中显示抗心律失常作用。
核心结论
- S10s基因治疗可能有效治疗心脏传导异常及相关心律失常。
研究设计与样本
- 研究使用腺相关病毒载体过表达S10s,注射至野生型和Scn5a单倍不足小鼠,进行膜片钳、光学标测、心电图分析和缺血再灌注实验。
- 研究还进行了体外和计算机模拟研究,以探索S10s基因治疗在人心脏背景下的效果。
主要发现
- 在Scn5a单倍不足小鼠心肌细胞中,S10s过表达增加细胞INa、最大动作电位上升速率和动作电位振幅。
- S10s基因治疗rescue Scn5a单倍不足小鼠的传导减慢,并预防野生型小鼠中缺血再灌注诱发的室性心动过速。
- S10s过表达增加人类诱导多能干细胞来源心肌细胞的最大动作电位上升速率,并在模拟人心室模型中预防可诱发心律失常。
临床怎么用
- S10s基因治疗可能为心脏传导异常及相关心律失常提供新的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Life-threatening arrhythmias are a well-established consequence of reduced cardiac sodium current (INa). Gene therapy approaches to increase INa have demonstrated potential benefits to prevent arrhythmias. However, the development of such therapies is hampered by the large size of sodium channels. In this study, SCN10A-short (S10s), a short transcript encoding the carboxy-terminal domain of the human neuronal sodium channel, was evaluated as a gene therapy target to increase INa and prevent arrhythmias. METHODS: Adeno-associated viral vector overexpressing S10s was injected into wild type and Scn5a-haploinsufficient mice on which patch-clamp studies, optical mapping, electrocardiogram analyses, and ischaemia reperfusion were performed. In vitro and in silico studies were conducted to further explore the effect of S10s gene therapy in the context of human hearts. RESULTS: Cardiac S10s overexpression increased cellular INa, maximal action potential upstroke velocity, and action potential amplitude in Scn5a-haploinsufficient cardiomyocytes. S10s gene therapy rescues conduction slowing in Scn5a-haploinsufficient mice and prevented ventricular tachycardia induced by ischaemia-reperfusion in wild type mice. S10s overexpression increased maximal action potential upstroke velocity in human inducible pluripotent stem cell-derived cardiomyocytes and prevented inducible arrhythmias in simulated human heart models. CONCLUSIONS: S10s gene therapy may be effective to treat cardiac conduction abnormalities and associated arrhythmias.
引用
- Wang J, Verkerk AO, Wilders R, et al. SCN10A-short gene therapy to restore conduction and protect against malignant cardiac arrhythmias. Eur Heart J. 2025. PMID: 39973098. doi:10.1093/eurheartj/ehaf053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。